InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
Stocks in this Quantisnow insightHealth Care
Quantisnow market dataNASDAQ
IFRX
InflaRx N.V.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2017
Get push alerts for IFRX
Full IFRX profile on Quantisnow Follow IFRX and get a push notification the moment its next story breaks.